Globus plans to boost sales with Alphatec acquisition

A black man and a white man shaking hands

Globus Medical has entered into an agreement to acquire Alphatec Holdings’ international operations and distribution channels.

It will also extend to Alphatec a 5-year senior secured credit facility amounting to up to $30 million. The $80 million cash acquisition is scheduled to complete by October 2016, as long as conditions are satisfied.


Join the world's top medtech executives virtually for the leading event in medtech — The Virtual MedTech Conference by AdvaMed

Expect the same high-quality education, world-class speakers and valuable business development in a virtual format. Experience more of the conference with on demand content and partnering, as well as livestreamed sessions.

As far as intentions go, Globus has plans to sell its own products through Alphatec’s international direct and distributor sales channels--a network that generated around $71 million in 2015 and has already brought in $15.6 million in Q1 2016. The agreement comes with the condition that Alphatec will supply Globus with its products for up to 5 years.

David Paul, chairman and CEO of Globus, noted that the acquisition will offer immediate access to Japan and will nearly double the company’s international sales. “In addition, we will be acquiring a talent pool of international sales professionals as well as an extensive network of international distributors,” he continued in his statement. “We expect the impact to be marginally accretive in 2017 as we work through our transition and integration plans and to provide up to 8 cents per share in incremental non-GAAP diluted earnings per share (EPS) in 2018 and beyond.”

Globus expects to see around $10 million of additional sales come in for Q4 2016 with earnings remaining neutral, except for acquisition-related costs. In 2017 Globus expects to bring in an additional $40 million in sales and to contribute non-GAAP EPS of around $0.03 to $0.05.

- here's the press release

Related Articles:
Globus Medical unveils new 'self-locking' spinal implant device
Globus owes $16M in J&J patent suit
Globus, CEO slapped with $1M fine for distributing unapproved device

Suggested Articles

Seven developers will provide digital health solutions aimed at the COVID-19 pandemic, including smartphone apps, wearables and big data programs.

Illumina will drop $8 billion to reacquire its former spinout, which after nearly five years is nearing completion of its cancer-seeking blood test.

The CE Mark for the system’s fourth iteration follows a July 2019 approval from the FDA.